Err

COVID 19 SCREENING

COVID 19 TESTING 

The IgG Test is the ABBOTT CMIA methodology 

WE CAN ALSO PROVIDE PCR SWAB CERTIFICATE FOR TRAVEL REQUIREMENTS 

COVID-19 PCR Swab Test
NB! THIS IS NOT A HOME TEST KIT. THE TEST IS CARRIED OUT WITHIN OUR CLINIC.


PCR (polymerase chain reaction) samples can come from several different sites in the patient. The simplest is the nasal swab  ...
£ 169.00
COVID-19 IgG Antibody Test
THIS IS AN ABBOTTS TEST 


NB! THIS IS NOT A HOME TEST KIT, THE TEST IS CARRIED OUT WITHIN OUR CLINIC.


This test is a venous blood draw test, which gets sent off for analysis.

IgG antibody testing can tell ...
£ 99.00
Covid PCR Saliva Testing

The PCR saliva test is designed to detect whether or not you are currently carrying the SARS-CoV-2 virus that causes COVID-19.

The test is CE marked and results are performed in an IS015189 UK laborato ...

£ 169.00
Covid Stool Testing
Cutting-edge viral RNA qPCR stool test measures levels of SARS-CoV-2, the virus that causes COVID-19.

Screen, monitor, or prevent transmission in patients at risk for COVID-19.

SARS-CoV-2 in stool may b ...
£ 199.00
C-reactive Protein (hCRP)
C-reactive protein (CRP) is a substance produced by the liver in response to inflammation in the body.

High CRP levels may also indicate that there's inflammation in the arteries of the heart, which m ...
£ 75.00
(-20.00%) £ 60.00
COVID-19 IgG And Rapid Test Bundle
£ 160.00
(-18.75%) £ 130.00
COVID-19 Rapid Antibody Test
NB! THIS IS NOT A HOME TEST KIT. THE TEST IS CARRIED OUT WITHIN OUR CLINIC.

This kit is intended for use as a tool to assist in the diagnosis of SARS-CoV-2 infections. It is also intended as a tool for ...
£ 65.00

The ability to accurately identify whether individuals are at risk for, infected with, or have an immune response to SARS-CoV-2 is essential to address the COVID-19 pandemic from both a personal and a public health perspective. Reliable testing is critical for:

  • Determining the state of an individual’s immune response to exposure.

  • Assessing whether an individual is contagious and needs to be quarantined.

  • Deciding if an individual is immune and can return to society without undue risk.

  • Facilitating contact tracing to reduce viral spread.

  • Determining the prevalence and natural history of this novel disease.



COVID 19 SYMPTOMS 

Indications

The majority of people with COVID-19 have uncomplicated or mild illness (81%), with non-specific symptoms such as fever, fatigue, cough (with or without sputum production), anorexia, malaise, muscle pain, sore throat, dyspnea, nasal congestion, or headache. Rarely, patients may also present with diarrhoea, nausea and vomiting. Loss of taste and smell has been reported early in the infection.

A relatively small proportion of people, particularly but by no means exclusively in those aged >70 years, will develop severe illness requiring oxygen therapy (14%) and approximately 5% will require intensive care unit treatment. Time from the onset of the infection to hospitalisation can be up to ~13 days. Of those critically ill, most will require mechanical ventilation. The most common diagnosis in severe COVID-19 patients is severe pneumonia; this can progress to acute respiratory distress syndrome, and life-threatening multi-organ dysfunction and death. Mortality has been estimated at between 1 and 2% of those infected, the higher figure in men.

Current testing for COVID-19 (SARS-CoV-2) is rapidly evolving. 

Clinical background and biology

Coronavirus disease 2019 (COVID-19) is a respiratory tract infection caused by a newly emergent coronavirus – Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) - which was first recognised in Wuhan, Hubei Province, China, in December 2019. Genetic sequencing of the virus suggests that SARS-CoV-2 is a betacoronavirus closely linked to SARS coronavirus 1.

The outbreak was declared a Public Health Emergency of International Concern on 30 January 2020, and has since spread globally, resulting in the 2019-20 coronavirus pandemic. Current measures are in place globally to reduce the spread of the virus, most commonly from droplets (person-to-person) but also from infected surfaces. The target is to reduce the reproduction number (R0) to <1.0 - i.e. < one person infected by one affected individual.


Testing is vital if we are to combat and contain this disease. We offer two types of testing : 

This Virus is so new we are still learning. The testing methods are continously improving until we can find a perfect way to screen exclusively for COVID 19. Our advice is to do both types of tests as currently the Rapid Antibody Tests has it limitations.

CoVID 19 PCR SWAB - SARS CoV- 2 RNA 

Molecular testing (PCR Swab) will identify people with the virus. 

Infectivity is now recognized to occur before the onset of symptoms and yet high titres of virus can be detected on upper airway surfaces in people who do not develop symptoms.

Infection with SARS-CoV-2, an RNA virus, is diagnosed using reverse-transcriptase PCR. The assays we use show a minimum sensitivity of 98% and a specificity of 100%, with no cross-reactivity with other viruses.

Coronavirus - COVID-19 (SARS-CoV-2) IgG Antibody

Antibody testing can tell whether a person has been previously infected. Most patients who recover from coronavirus have been found to produce antibodies, but it is not yet known if an individual with a positive result showing presence of IgG levels following being infected with SARS-CoV-2 will be protected, either fully or partially from future infection, or for how long protective immunity may last.

Testing should be undertaken 14 days or more following exposure or onset of symptoms. The incubation period of COVID-19 ranges from between 1 to 14 days, with the majority of cases manifesting with symptoms at 3 - 5 days. The most common symptoms of COVID-19 are fever, tiredness, dry cough and difficulty breathing. These symptoms have the potential to develop into a very severe acute respiratory illness. Evidence shows that fatality rates increase with age, gender, body weight, ethnicity and comorbidities.

The host immune system reacts to the infection by SARS-CoV-2 by producing antibodies from a few days to 2 weeks after the onset of symptoms. Specific IgG antibodies are produced in the later stages of infection to SARS-CoV-2, and are detectable after RNA is no longer detectable.

The persistence of IgG antibodies allows identification of people who have been infected by SARS-CoV-2. Test development relating to SARS-CoV-2 is rapidly evolving. 

Interpretation of Results

COV-2 IgG

< 1.4

Not Detected

(Negative)

COV-2 IgG

>= 1.4

Detected

(Positive)



The Video shows how the two different tests works 

 

SECURE PAYmenT

Credit Cards : Visa, Mastercard, Amex

Contact us

Send a message

+44 203 771 9927

Monday - Friday 9.00 am-6.00 pm, Sat 10am - 5pm , Sunday Flexible